Titre : Histone-lysine N-methyltransferase

Histone-lysine N-methyltransferase : Questions médicales fréquentes

Termes MeSH sélectionnés :

Microarray Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Histone-lysine N-methyltransferase : Questions médicales les plus fréquentes", "headline": "Histone-lysine N-methyltransferase : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Histone-lysine N-methyltransferase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-29", "dateModified": "2025-04-23", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Histone-lysine N-methyltransferase" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Histone méthyltransférases", "url": "https://questionsmedicales.fr/mesh/D000076983", "about": { "@type": "MedicalCondition", "name": "Histone méthyltransférases", "code": { "@type": "MedicalCode", "code": "D000076983", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.555.500.800.200" } } }, "about": { "@type": "MedicalCondition", "name": "Histone-lysine N-methyltransferase", "alternateName": "Histone-Lysine N-Methyltransferase", "code": { "@type": "MedicalCode", "code": "D011495", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jasmin Mecinović", "url": "https://questionsmedicales.fr/author/Jasmin%20Mecinovi%C4%87", "affiliation": { "@type": "Organization", "name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands." } }, { "@type": "Person", "name": "Abbas H K Al Temimi", "url": "https://questionsmedicales.fr/author/Abbas%20H%20K%20Al%20Temimi", "affiliation": { "@type": "Organization", "name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands." } }, { "@type": "Person", "name": "Danny C Lenstra", "url": "https://questionsmedicales.fr/author/Danny%20C%20Lenstra", "affiliation": { "@type": "Organization", "name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands." } }, { "@type": "Person", "name": "Paul B White", "url": "https://questionsmedicales.fr/author/Paul%20B%20White", "affiliation": { "@type": "Organization", "name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands. Floris.Rutjes@ru.nl." } }, { "@type": "Person", "name": "Ping Qian", "url": "https://questionsmedicales.fr/author/Ping%20Qian", "affiliation": { "@type": "Organization", "name": "Chemistry and Material Science Faculty, Shandong Agricultural University, Daizong Road No.61, Tai'an, 271018, P.R. China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Research progress in protein microarrays: Focussing on cancer research.", "datePublished": "2022-10-31", "url": "https://questionsmedicales.fr/article/36316278", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/prca.202200036" } }, { "@type": "ScholarlyArticle", "name": "Diagnostic Yield of Exome Sequencing in Fetuses with Sonographic Features of Skeletal Dysplasias but Normal Karyotype or Chromosomal Microarray Analysis: A Systematic Review.", "datePublished": "2023-05-30", "url": "https://questionsmedicales.fr/article/37372383", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/genes14061203" } }, { "@type": "ScholarlyArticle", "name": "Assessing the value of second-trimester nasal bone hypoplasia in predicting chromosomal abnormalities: a retrospective chromosomal microarray analysis of 351 fetuses.", "datePublished": "2022-10-21", "url": "https://questionsmedicales.fr/article/36269386", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00404-022-06808-6" } }, { "@type": "ScholarlyArticle", "name": "Estimation on risk of spontaneous abortions by genomic disorders from a meta-analysis of microarray results on large case series of pregnancy losses.", "datePublished": "2023-04-04", "url": "https://questionsmedicales.fr/article/37013615", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/mgg3.2181" } }, { "@type": "ScholarlyArticle", "name": "Epitranscriptomic profiling of m6A RNA methylation in renal epithelial tubular cells stimulated with calcium oxalate crystals through microarray analysis.", "datePublished": "2023-03-22", "url": "https://questionsmedicales.fr/article/36947229", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00240-023-01425-7" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Transferases", "item": "https://questionsmedicales.fr/mesh/D014166" }, { "@type": "ListItem", "position": 5, "name": "One-carbon group transferases", "item": "https://questionsmedicales.fr/mesh/D019875" }, { "@type": "ListItem", "position": 6, "name": "Methyltransferases", "item": "https://questionsmedicales.fr/mesh/D008780" }, { "@type": "ListItem", "position": 7, "name": "Protein Methyltransferases", "item": "https://questionsmedicales.fr/mesh/D011496" }, { "@type": "ListItem", "position": 8, "name": "Histone méthyltransférases", "item": "https://questionsmedicales.fr/mesh/D000076983" }, { "@type": "ListItem", "position": 9, "name": "Histone-lysine N-methyltransferase", "item": "https://questionsmedicales.fr/mesh/D011495" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Histone-lysine N-methyltransferase - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Histone-lysine N-methyltransferase", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Histone-lysine N-methyltransferase", "description": "Comment diagnostiquer une dysfonction des N-méthyltransférases ?\nQuels tests sont utilisés pour évaluer l'activité des N-méthyltransférases ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels marqueurs biologiques sont associés aux N-méthyltransférases ?\nPeut-on utiliser l'imagerie pour diagnostiquer des anomalies ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Histone-lysine N-methyltransferase", "description": "Quels symptômes sont liés à une dysfonction des N-méthyltransférases ?\nLes symptômes sont-ils spécifiques à une maladie ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes peuvent-ils évoluer avec le temps ?\nLes symptômes sont-ils visibles à l'examen physique ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Histone-lysine N-methyltransferase", "description": "Peut-on prévenir les dysfonctionnements des N-méthyltransférases ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes exercices physiques aident-ils à prévenir les dysfonctionnements ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Histone-lysine N-methyltransferase", "description": "Quels traitements ciblent les N-méthyltransférases ?\nLa thérapie génique est-elle une option ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des effets secondaires aux traitements ?\nLes traitements sont-ils efficaces à long terme ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Histone-lysine N-methyltransferase", "description": "Quelles complications peuvent survenir avec des dysfonctionnements ?\nLes complications sont-elles réversibles ?\nY a-t-il des complications neurologiques possibles ?\nLes complications affectent-elles la qualité de vie ?\nComment gérer les complications liées aux N-méthyltransférases ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Histone-lysine N-methyltransferase", "description": "Quels sont les principaux facteurs de risque ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nLes maladies chroniques sont-elles des facteurs de risque ?\nY a-t-il des facteurs génétiques impliqués ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des N-méthyltransférases ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des N-méthyltransférases ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques et des méthodes de chromatographie peuvent être employés." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent être nécessaires pour évaluer les modifications épigénétiques." } }, { "@type": "Question", "name": "Quels marqueurs biologiques sont associés aux N-méthyltransférases ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de méthylation des histones peuvent servir de marqueurs biologiques." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour diagnostiquer des anomalies ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie n'est pas couramment utilisée pour diagnostiquer ces anomalies." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une dysfonction des N-méthyltransférases ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de l'expression génique peuvent entraîner divers symptômes, selon le tissu." } }, { "@type": "Question", "name": "Les symptômes sont-ils spécifiques à une maladie ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils peuvent varier selon la maladie et le type de tissu affecté." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines dysfonctions peuvent entraîner des troubles neurologiques." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils évoluer avec le temps ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'évolution des symptômes dépend de la progression de la maladie sous-jacente." } }, { "@type": "Question", "name": "Les symptômes sont-ils visibles à l'examen physique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, les symptômes ne sont pas visibles et nécessitent des tests spécifiques." } }, { "@type": "Question", "name": "Peut-on prévenir les dysfonctionnements des N-méthyltransférases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à éviter ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains agents chimiques et toxines peuvent influencer la fonction enzymatique." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des dépistages peuvent être utiles pour les personnes à risque génétique élevé." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut influencer la santé épigénétique et réduire les risques." } }, { "@type": "Question", "name": "Les exercices physiques aident-ils à prévenir les dysfonctionnements ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut avoir un impact positif sur la santé cellulaire." } }, { "@type": "Question", "name": "Quels traitements ciblent les N-méthyltransférases ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques des N-méthyltransférases sont en cours de développement." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie génique pourrait corriger les anomalies liées aux N-méthyltransférases." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, comme tout traitement, des effets secondaires peuvent survenir." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces à long terme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité à long terme dépend de la maladie et de la réponse individuelle au traitement." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des dysfonctionnements ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications peuvent inclure des cancers et d'autres maladies génétiques." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Y a-t-il des complications neurologiques possibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles neurologiques peuvent survenir en raison de modifications épigénétiques." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent significativement impacter la qualité de vie des patients." } }, { "@type": "Question", "name": "Comment gérer les complications liées aux N-méthyltransférases ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux et l'exposition à des agents environnementaux sont des facteurs clés." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de dysfonctionnement enzymatique augmente avec l'âge." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut augmenter le risque de dysfonctionnement." } }, { "@type": "Question", "name": "Les maladies chroniques sont-elles des facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies chroniques peuvent prédisposer à des dysfonctionnements enzymatiques." } }, { "@type": "Question", "name": "Y a-t-il des facteurs génétiques impliqués ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations génétiques peuvent augmenter le risque de dysfonctionnement." } } ] } ] }

Sources (10000 au total)

Diagnostic Yield of Exome Sequencing in Fetuses with Sonographic Features of Skeletal Dysplasias but Normal Karyotype or Chromosomal Microarray Analysis: A Systematic Review.

Skeletal dysplasias are a group of diseases characterized by bone and joint abnormalities, which can be detected during prenatal ultrasound. Next-generation sequencing has rapidly revolutionized molec...

Assessing the value of second-trimester nasal bone hypoplasia in predicting chromosomal abnormalities: a retrospective chromosomal microarray analysis of 351 fetuses.

To evaluate the value of fetal nasal bone hypoplasia and other prenatal risk factors in predicting chromosomal abnormalities.... In this retrospective cohort study, we collected data on singleton pregnancies diagnosed with fetal nasal bone hypoplasia during second-trimester ultrasound. Fetal karyotyping and chromosomal microarr... Our final analysis included 351 pregnancies, of which 62 (17.7%) fetuses had chromosomal abnormalities, including 36 cases of trisomy-21, six cases of trisomy-18, one case each of trisomy-13, and 47, ... Nasal bone hypoplasia is a highly specific soft marker that is associated with multiple chromosomal abnormalities. The risk of chromosomal abnormalities increases when combined with structural abnorma...

Identification of key genes and immune cell infiltration in recurrent implantation failure: A study based on integrated analysis of multiple microarray studies.

Recurrent implantation failure (RIF) refers to a challenging topic in assisted reproductive technology (ART), the etiology of which may be attributed to impaired endometrial receptivity; however, the ... Four RIF microarray datasets were obtained from the Gene Expression Omnibus database and integrated by the "sva" R package. The differentially expressed genes (DEGs) were analyzed using the "limma" pa... 236 genes were differentially expressed in the endometrium of the RIF group. Functional enrichment analysis demonstrated that the biological functions of DEGs were mainly correlated to the immune-rela... Abnormal immune response regulation of endometrium contributes to the occurrence of RIF, and γδ T cells may be the pivotal immune cells causing RIF. At the same time, the novel hub genes identified wi...

High-throughput analysis of amniotic fluid proteins associated with histological chorioamnionitis in preterm premature rupture of membranes using an antibody-based microarray.

To identify potential proteins in the amniotic fluid (AF) that may be associated with histologic chorioamnionitis (HCA) in patients with preterm premature rupture of membranes (PPROM) using antibody-b... This was a retrospective cohort study involving 100 singleton pregnant women with PPROM at 24-34 weeks who underwent amniocentesis and delivered within 120 h of amniocentesis. First, the AF proteomes ... Of 507 proteins assessed in the microarray analysis, 46 showed significant intergroup differences. Further quantification confirmed that the levels of EN-RAGE, IL-6, MMP-9, TNFR2, SPARC, TSP2, and uPA... Using protein-antibody microarray technology, we discovered several potential AF proteins (EN-RAGE, IL-6, MMP-9, and TNFR2) independently associated with HCA in patients with PPROM. Furthermore, we de...

DNER and GNL2 are differentially m6A methylated in periodontitis in comparison with periodontal health revealed by m6A microarray of human gingival tissue and transcriptomic analysis.

This study aims to investigate the differences in the epigenomic patterns of N6-methyladenosine (m6A) methylation in gingival tissues between patients with periodontitis (PD) and healthy controls, ide... As a multifactorial disease, PD involves multiple genetic and environmental effects. The m6A modification is the most prevalent internal mRNA modification and linked to various inflammatory diseases. ... An m6A microarray of human gingival tissues was conducted in eight subjects: four diagnosed with PD and four healthy controls. Microarray analysis was performed to identify the differentially m6A meth... In total, 458 DMGs, 750 DEGs, and 279 DMEGs were identified based on our microarray. Pathway analyses conducted for the DMEGs revealed that biological functions were mainly involved in the regulation ... The current study exhibited a distinct m6A epitranscriptome, identified and verified two PD-related biomarkers (DNER and GNL2), which may provide novel insights into revealing the new molecular mechan...